Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury

Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury
Neuren Pharmaceuticals chief executive Jon Pilcher says the Kiwi firm is in a privileged position. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
Neuren Pharmaceuticals' boss Jon Pilcher says he was punching the air after leaving a recent successful meeting with the US Food and Drug Administration.Neuren, a local company which develops treatments for neurological disorders including Rett syndrome, has been cleared to begin phase-three trials for the drug NNZ-2591 to treat Phelan-McDermid syndrome. It will be the first-ever phase-three trial in children with the rare genetic condition.The disorders Neuren targets for treatment with its drugs are often debilitating and can ha...

More Markets

F&P Healthcare, Fletcher drive NZ stocks lower
Markets Market Close

F&P Healthcare, Fletcher drive NZ stocks lower

Dips for Fisher and Paykel Healthcare and Fletcher Building drive market down.

Jamie Gray 16 May 2025
Two executives depart Bremworth
Primary Sector

Two executives depart Bremworth

The two resignations follow chief executive Greg Smith's departure. 

Riley Kennedy 16 May 2025
Forsyth Barr sees future upside in Briscoe initiatives
Retail

Forsyth Barr sees future upside in Briscoe initiatives

Management gave details on the company's roadmap for growth at the AGM on Thursday.

Gregor Thompson 16 May 2025